ืืฃ ืืืืชAXGN โข NASDAQ
add
AxoGen, Inc Common Stock
โ13.43ย โ$
ืืคื ื ืคืชืืืช ืืืกืืจ:(0.89%)+0.12
โ13.55ย โ$
ืกืืืจ: 30 ืืืืื, 04:49:16 GMT-4โ · USD · NASDAQ · ืืชื ืืืชืืจ
ืื ืืื ืืืจ ืขืจื ืฉืจืฉืื ืืืจื"ืืืืฉืจื ืืจืืฉื ืฉื ืืืืจื ื ืืฆื ืืืจื"ื
ืฉืขืจ ืกืืืจื ืงืืื
โ12.99ย โ$
ืืืื ืืืื
โ13.11ย โ$ - โ14.39ย โ$
ืืืื ืฉื ืชื
โ7.34ย โ$ - โ21.00ย โ$
ืฉืืื ืฉืืง
611.66Mโ USD
ื ืคื ืืกืืจ ืืืืฆืข
949.94Kโ
ืืืคืื ืจืืื
-
ืชืฉืืืช ืืืืืื ื
-
ืืืจืกื ืขืืงืจืืช
NASDAQ
ืืืืฉืืช
ืืกืคืื
ืืฆืืจืช ืืื ืกื
ืืื ืกื
ืจืืื ื ืงื
(USD) | ืืจืฅ 2025info | ืฉืื ืื ืืฉื ื ืืฉื ื |
---|---|---|
ืืื ืกื | 48.56Mโ | 17.36% |
ืืืฆืืืช ืชืคืขืืืืืช | 36.59Mโ | โ-1.58% |
ืจืืื ื ืงื | โ-3.83Mโ | 42.22% |
ืฉืืื ืจืืื ื ืงื | โ-7.90 | 50.75% |
ืจืืืืื ืืื ืื | โ-0.02 | 66.67% |
ืจืืื ืืคื ื ืจืืืืช, ืืืกืื, ืคืืช ืืืคืืชืืช | 134.00Kโ | 104.50% |
ืฉืืขืืจ ืืก ืืคืงืืืื | โ | โ |
ืืืื
ืกื ืื ืื ืืกืื
ืืืืช ืืืืืช
(USD) | ืืจืฅ 2025info | ืฉืื ืื ืืฉื ื ืืฉื ื |
---|---|---|
ืืืืื ืื ืืืฉืงืขืืช ืืืืื ืงืฆืจ | 22.07Mโ | 25.15% |
ืกื ืื ืื ืืกืื | 196.16Mโ | 5.17% |
ืืืืช ืืืืืช | 90.80Mโ | โ-2.74% |
ืืื ืขืฆืื ืืืื | 105.36Mโ | โ |
ืืื ืขืืื | 45.54Mโ | โ |
ืืืคืื ืืื | 5.60 | โ |
ืชืฉืืื ืขื ืื ืืกืื | โ-2.08% | โ |
ืชืฉืืื ืขื ืืื | โ-2.36% | โ |
ืชืืจืื ืืืืื ืื
ืฉืื ืื ืืฉืืื ืืืืื ืื
(USD) | ืืจืฅ 2025info | ืฉืื ืื ืืฉื ื ืืฉื ื |
---|---|---|
ืจืืื ื ืงื | โ-3.83Mโ | 42.22% |
ืืืืื ืื ืืคืขืืืืช ืฉืืืคืช | โ-13.18Mโ | โ-7.44% |
ืืืืื ืืืฉืงืขืืช | 1.34Mโ | 141.19% |
ืืืืื ืืืืืื | 2.38Mโ | 1,067.65% |
ืฉืื ืื ืืฉืืื ืืืืื ืื | โ-9.46Mโ | 38.24% |
ืชืืจืื ืืืืื ืื ืคื ืื | โ-12.34Mโ | โ-9.71% |
ืืืืข ืืืื
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
ืชืืจืื ืืงืื
2002
ืืฉืจืืื ืจืืฉืืื
ืืชืจ
ืขืืืืื
452